GLP-1 receptor agonists are given preference over DPP-4 inhibitors in dual- and triple-therapy intensification regimens after metformin by the AACE and by the ADA/European Association for the Study of Diabetes as a tier-2 therapy when hypoglycaemia and weight concerns are paramount (1,2). This evidence concerns the gene DPP4 and diabetes mellitus.